Literature DB >> 19234170

NK-dependent increases in CCL22 secretion selectively recruits regulatory T cells to the tumor microenvironment.

Adam W Mailloux1, M Rita I Young.   

Abstract

Tumor-induced immune suppression involves the accumulation of immune-suppressive infiltrates in the microenvironment. This study demonstrates increased numbers of CD4(+)CD25(+)FoxP3(+) regulatory T cells (Tregs) in the lungs of C57BL/6 mice bearing a metastatic Lewis lung carcinoma (LLC) variant. These Tregs suppressed the proliferation of endogenous CD4(+)CD25(-) cells and expressed higher levels of the chemokine receptor CCR4 than other types of T cells. LLC-bearing lungs secreted elevated levels of the CCR4-associated chemokine CCL22 compared with normal lungs. However, CCL22 was not secreted by LLC or normal epithelial controls, suggesting that CCL22 is secreted by a nonepithelial component of the microenvironment. Migration assays revealed that medium conditioned by LLC-bearing lungs selectively recruited Tregs at higher frequencies than did medium conditioned by normal lungs. Neutralization of CCL22 significantly reduced this selective recruitment toward both conditioned media. A series of immunomagnetic isolations, FACS, and flow cytometric analyses were used to isolate different cellular fractions from both normal and LLC-bearing lungs. When isolated, only the NK-containing fractions secreted CCL22, and the same fraction isolated from LLC-bearing lungs secreted higher levels. Depletion of NK cells from both normal and LLC-bearing lung tissue significantly reduced CCL22 secretion, suggesting that a large portion of secreted CCL22 is NK cell dependent. Flow cytometric analysis of the lung NK compartments revealed no significant increase in NK cell numbers across LLC-bearing lung tissue as a whole as compared with normal tissue. However, immunofluorescent staining revealed an increased frequency of NK cells at the tumor periphery that were closely associated with the elevated FoxP3(+) infiltrate.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19234170      PMCID: PMC3337694          DOI: 10.4049/jimmunol.0801124

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  55 in total

1.  Kinetics of the early recruitment of leukocyte subsets at the sites of tumor cells in the lungs: natural killer (NK) cells rapidly attract monocytes but not lymphocytes in the surveillance of micrometastasis.

Authors:  Kiyoshi Shingu; Andreas Helfritz; Susanne Kuhlmann; Margot Zielinska-Skowronek; Roland Jacobs; Reinhold E Schmidt; Reinhard Pabst; Stephan von Hörsten
Journal:  Int J Cancer       Date:  2002-05-01       Impact factor: 7.396

2.  Control of regulatory T cell development by the transcription factor Foxp3.

Authors:  Shohei Hori; Takashi Nomura; Shimon Sakaguchi
Journal:  Science       Date:  2003-01-09       Impact factor: 47.728

Review 3.  Tumor-induced immune dysfunctions caused by myeloid suppressor cells.

Authors:  V Bronte; P Serafini; E Apolloni; P Zanovello
Journal:  J Immunother       Date:  2001 Nov-Dec       Impact factor: 4.456

4.  Gr-1+ myeloid cells derived from tumor-bearing mice inhibit primary T cell activation induced through CD3/CD28 costimulation.

Authors:  S A Kusmartsev; Y Li; S H Chen
Journal:  J Immunol       Date:  2000-07-15       Impact factor: 5.422

5.  Foxp3 programs the development and function of CD4+CD25+ regulatory T cells.

Authors:  Jason D Fontenot; Marc A Gavin; Alexander Y Rudensky
Journal:  Nat Immunol       Date:  2003-03-03       Impact factor: 25.606

6.  An essential role for Scurfin in CD4+CD25+ T regulatory cells.

Authors:  Roli Khattri; Tom Cox; Sue-Ann Yasayko; Fred Ramsdell
Journal:  Nat Immunol       Date:  2003-03-03       Impact factor: 25.606

7.  CCL17 and CCL22 chemokines within tumor microenvironment are related to accumulation of Foxp3+ regulatory T cells in gastric cancer.

Authors:  Yoshiki Mizukami; Koji Kono; Yoshihiko Kawaguchi; Hidenori Akaike; Kazuyasu Kamimura; Hidemitsu Sugai; Hideki Fujii
Journal:  Int J Cancer       Date:  2008-05-15       Impact factor: 7.396

8.  CD4 regulatory T cells prevent lethal autoimmunity in IL-2Rbeta-deficient mice. Implications for the nonredundant function of IL-2.

Authors:  Thomas R Malek; Aixin Yu; Vladimir Vincek; Paul Scibelli; Lin Kong
Journal:  Immunity       Date:  2002-08       Impact factor: 31.745

9.  Immunization with Melan-A peptide-pulsed peripheral blood mononuclear cells plus recombinant human interleukin-12 induces clinical activity and T-cell responses in advanced melanoma.

Authors:  Amy C Peterson; Helena Harlin; Thomas F Gajewski
Journal:  J Clin Oncol       Date:  2003-06-15       Impact factor: 44.544

10.  Unique chemotactic response profile and specific expression of chemokine receptors CCR4 and CCR8 by CD4(+)CD25(+) regulatory T cells.

Authors:  A Iellem; M Mariani; R Lang; H Recalde; P Panina-Bordignon; F Sinigaglia; D D'Ambrosio
Journal:  J Exp Med       Date:  2001-09-17       Impact factor: 14.307

View more
  36 in total

1.  Higher circulating levels of chemokine CCL22 in patients with breast cancer: evaluation of the influences of tumor stage and chemokine gene polymorphism.

Authors:  A Jafarzadeh; H Fooladseresht; K Minaee; M R Bazrafshani; A Khosravimashizi; M Nemati; M Mohammadizadeh; M M Mohammadi; A Ghaderi
Journal:  Tumour Biol       Date:  2014-10-22

2.  Tolerogen-induced interferon-producing killer dendritic cells (IKDCs) protect against EAE.

Authors:  Eduardo Huarte; Agnieszka Rynda-Apple; Carol Riccardi; Jerod A Skyberg; Sarah Golden; Maryclare F Rollins; Andrew G Ramstead; Larissa O Jackiw; Massimo Maddaloni; David W Pascual
Journal:  J Autoimmun       Date:  2011-10-22       Impact factor: 7.094

3.  Treg-recruiting microspheres prevent inflammation in a murine model of dry eye disease.

Authors:  Michelle L Ratay; Andrew J Glowacki; Stephen C Balmert; Abhinav P Acharya; Julia Polat; Lawrence P Andrews; Morgan V Fedorchak; Joel S Schuman; Dario A A Vignali; Steven R Little
Journal:  J Control Release       Date:  2017-05-10       Impact factor: 9.776

4.  Decreased percentage of CD4+FoxP3+ cells in bronchoalveolar lavage from lung transplant recipients correlates with development of bronchiolitis obliterans syndrome.

Authors:  Sangeeta M Bhorade; Hong Chen; Luciana Molinero; Chuanhong Liao; Edward R Garrity; Wickii T Vigneswaran; Rebecca Shilling; Anne Sperling; Anita Chong; Maria-Luisa Alegre
Journal:  Transplantation       Date:  2010-09-15       Impact factor: 4.939

5.  Bioinspired controlled release of CCL22 recruits regulatory T cells in vivo.

Authors:  Siddharth Jhunjhunwala; Giorgio Raimondi; Andrew J Glowacki; Sherri J Hall; Dan Maskarinec; Stephen H Thorne; Angus W Thomson; Steven R Little
Journal:  Adv Mater       Date:  2012-07-23       Impact factor: 30.849

Review 6.  Chemokines in health and disease.

Authors:  Dayanidhi Raman; Tammy Sobolik-Delmaire; Ann Richmond
Journal:  Exp Cell Res       Date:  2011-01-09       Impact factor: 3.905

Review 7.  Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer.

Authors:  Sergei I Grivennikov; Michael Karin
Journal:  Cytokine Growth Factor Rev       Date:  2009-12-16       Impact factor: 7.638

8.  The role of regulatory T cells in cancer.

Authors:  Tai-You Ha
Journal:  Immune Netw       Date:  2009-12-31       Impact factor: 6.303

9.  Successful immunotherapy with IL-2/anti-CD40 induces the chemokine-mediated mitigation of an immunosuppressive tumor microenvironment.

Authors:  Jonathan M Weiss; Timothy C Back; Anthony J Scarzello; Jeff J Subleski; Veronica L Hall; Jimmy K Stauffer; Xin Chen; Dejan Micic; Kory Alderson; William J Murphy; Robert H Wiltrout
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-05       Impact factor: 11.205

10.  IL-18-primed helper NK cells collaborate with dendritic cells to promote recruitment of effector CD8+ T cells to the tumor microenvironment.

Authors:  Jeffrey L Wong; Erik Berk; Robert P Edwards; Pawel Kalinski
Journal:  Cancer Res       Date:  2013-06-12       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.